China Resources Pharma's Investment Arm to Divest 5.88% Stake in Tianmai Biotech

Stock News

03/16

China Resources Pharma (03320) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., has initiated the potential sale of approximately 5.88% of its equity interest in Hefei Tianmai Biotech Development Co., Ltd. (Tianmai Biotech). The divestment will be conducted through a public listing on the Shanghai United Assets and Equity Exchange, with a preliminary reserve price set at around RMB 510 million. This potential transaction is separate and independent from the sale of certain equity interests in Tianmai Biotech by China Resources Pharmaceutical Investment and its subsidiaries. As of the date of this announcement, China Resources Pharmaceutical Investment and its subsidiaries collectively hold approximately 23.75% of the equity in Tianmai Biotech.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1106129332"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106129332\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106129332?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 21:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106129332","market":"us","top_or_hot":-1,"title":"China Resources Pharma's Investment Arm to Divest 5.88% Stake in Tianmai Biotech","media":"Stock News","content":"<p>China Resources Pharma (03320) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., has initiated the potential sale of approximately 5.88% of its equity interest in Hefei Tianmai Biotech Development Co., Ltd. (Tianmai Biotech). The divestment will be conducted through a public listing on the Shanghai United Assets and Equity Exchange, with a preliminary reserve price set at around RMB 510 million. This potential transaction is separate and independent from the sale of certain equity interests in Tianmai Biotech by China Resources Pharmaceutical Investment and its subsidiaries. As of the date of this announcement, China Resources Pharmaceutical Investment and its subsidiaries collectively hold approximately 23.75% of the equity in Tianmai Biotech.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Resources Pharma's Investment Arm to Divest 5.88% Stake in Tianmai Biotech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Resources Pharma's Investment Arm to Divest 5.88% Stake in Tianmai Biotech\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-03-16 21:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>China Resources Pharma (03320) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., has initiated the potential sale of approximately 5.88% of its equity interest in Hefei Tianmai Biotech Development Co., Ltd. (Tianmai Biotech). The divestment will be conducted through a public listing on the Shanghai United Assets and Equity Exchange, with a preliminary reserve price set at around RMB 510 million. This potential transaction is separate and independent from the sale of certain equity interests in Tianmai Biotech by China Resources Pharmaceutical Investment and its subsidiaries. As of the date of this announcement, China Resources Pharmaceutical Investment and its subsidiaries collectively hold approximately 23.75% of the equity in Tianmai Biotech.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XBI","symbol_name":"SPDR S&P Biotech ETF","start_time":0,"source_url":"","article_id":"1106129332","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106129332","pubTimestamp":1773668897,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"China Resources Pharma (03320) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., has initiated the potential sale of approximately 5.88% of its equity...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159837":"生物科技","XBI":"SPDR S&P Biotech ETF","03320":"华润医药","BK4588":"碎股","BK1191":"制药","BK1570":"华润系","BK4585":"ETF&股票定投概念","BK4581":"高盛持仓"},"translate_title":"华润医药投资部门将剥离天迈生物5.88%股权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159837":1,"03320":1,"XBI":1,"HBImain":1},"content_text":"China Resources Pharma (03320) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., has initiated the potential sale of approximately 5.88% of its equity interest in Hefei Tianmai Biotech Development Co., Ltd. (Tianmai Biotech). The divestment will be conducted through a public listing on the Shanghai United Assets and Equity Exchange, with a preliminary reserve price set at around RMB 510 million. This potential transaction is separate and independent from the sale of certain equity interests in Tianmai Biotech by China Resources Pharmaceutical Investment and its subsidiaries. As of the date of this announcement, China Resources Pharmaceutical Investment and its subsidiaries collectively hold approximately 23.75% of the equity in Tianmai Biotech.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}